In the 31person study, patients with cutaneous sarcoidosis who received a high dose of the drug improved by an average of 22.3 points on a 165-point scale of disease activity, compared to 0.7 points for patients who received placebo." Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study "A phase 2 study evaluating brepocitinib in patients with cutaneous sarcoidosis (CS) has become the first industry-sponsored, placebo-controlled trial to generate a positive readout in the indication, according to Priovant." Top 10 most anticipated drug launches of 2026 Roivant Sciences exited 2025 with evidence that its bet on Pfizers TYK2/JAK1 inhibitor brepocitinib may pay off
That mix of motivations matters for insurers because public drug plans generally only cover GLP1s for type 2 diabetes, leaving most obesityfocused use in the private market, the survey said
4, 5, and 6 are prepared with the appropriate amounts of a JNK inhibitor, such as any one of the JNK inhibitors described herein, and medium chain triglyceride (CRODAMOL, GTCC-LQ-(MV), PhEur) as shown in the below table (Table D).Formulations The formulations are prepared by adding the target weight percentage of the JNK inhibitor to the appropriate amount of medium chain triglyceride
Ozempic, Wegovy, Mounjaro- these injectable medications mimic a naturally occurring hormone called GLP-1 (glucagon-like peptide-1) that regulates blood sugar, reduces appetite, and supports weight management
10.1146/annurev.physiol.66.032102.150251 Annu
: BPC 157 , 400 500
